129 related articles for article (PubMed ID: 10663611)
1. Gene gun application in the generation of effector T cells for adoptive immunotherapy.
Tanigawa K; Yu H; Sun R; Nickoloff BJ; Chang AE
Cancer Immunol Immunother; 2000 Feb; 48(11):635-43. PubMed ID: 10663611
[TBL] [Abstract][Full Text] [Related]
2. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells.
Aruga A; Shu S; Chang AE
Cancer Immunol Immunother; 1995 Nov; 41(5):317-24. PubMed ID: 8536278
[TBL] [Abstract][Full Text] [Related]
4. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
Aruga A; Aruga E; Cameron MJ; Chang AE
J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
[TBL] [Abstract][Full Text] [Related]
5. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo stimulation of tumor-draining lymph node cells from lung cancer patients: a potential resource for adoptive immunotherapy.
Shan B; Li Q; He M; He Y
Cell Mol Immunol; 2008 Aug; 5(4):307-13. PubMed ID: 18761819
[TBL] [Abstract][Full Text] [Related]
8. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine.
Mahvi DM; Burkholder JK; Turner J; Culp J; Malter JS; Sondel PM; Yang NS
Hum Gene Ther; 1996 Aug; 7(13):1535-43. PubMed ID: 8864754
[TBL] [Abstract][Full Text] [Related]
9. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
10. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes.
Arca MJ; Krauss JC; Strome SE; Cameron MJ; Chang AE
Cancer Immunol Immunother; 1996 May; 42(4):237-45. PubMed ID: 8665571
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
12. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
13. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
Li B; VanRoey MJ; Jooss K
Clin Immunol; 2007 May; 123(2):155-65. PubMed ID: 17320482
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.
Tian H; Shi G; Yang G; Zhang J; Li Y; Du T; Wang J; Xu F; Cheng L; Zhang X; Dai L; Chen X; Zhang S; Yang Y; Yu D; Wei Y; Deng H
BMC Cancer; 2014 Jan; 14():48. PubMed ID: 24475975
[TBL] [Abstract][Full Text] [Related]
15. Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function.
Miller G; Pillarisetty VG; Shah AB; Lahrs S; Xing Z; DeMatteo RP
J Immunol; 2002 Sep; 169(6):2875-85. PubMed ID: 12218100
[TBL] [Abstract][Full Text] [Related]
16. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
Aruga A; Aruga E; Chang AE
Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
[TBL] [Abstract][Full Text] [Related]
17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
19. [GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro].
He SB; Sun K; Wang L; Li DC; Zhang YY
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):410-4. PubMed ID: 20819479
[TBL] [Abstract][Full Text] [Related]
20. Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity.
Aruga A; Tanigawa K; Aruga E; Yu H; Chang AE
Cancer Gene Ther; 1999; 6(1):89-95. PubMed ID: 10078968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
